In the last decade, anti-CD19 CAR-T cell therapy has led to a treatment paradigm shift for B-
cell non-Hodgkin lymphomas, first with the approval for relapsed/refractory (R/R) large B-cell …

Simple Summary Despite the impressive efficacy of chimeric antigen receptor-T (CAR-T) cell
therapy in the treatment of some subtypes of lymphomas, many patients are either not …

Recently, multiple chimeric antigen receptor T‐cell (CAR‐T)‐based therapies have been
approved for treating hematological malignancies, targeting CD19 and B‐cell maturation …

Angioimmunoblastic T-cell lymphoma (AITL) is the second most frequent subtype of mature
T-cell lymphoma (MTCL) in the Western world. It derives from the monoclonal proliferation of …

To date, mAbs have had limited success in improving outcomes for patients with T-cell
lymphomas. Preclinical data suggest that anti–T-cell receptor Vβ-segment mAbs are a novel …

Extranodal NK-/T-cell lymphoma (ENKTCL) is a rare and highly aggressive malignancy with
significant racial and geographic variations worldwide. In addition to the formerly “nasal …

Chimeric antigen receptor T cell therapy has become an important immunotherapeutic tool
for overcoming cancers. However, the efficacy of CAR-T cell therapy in solid tumors is …

Peripheral T cell lymphoma (PTCL) represents a group of heterogeneous hematological
malignancies, which are notoriously challenging to treat and outcomes are typically poor …

Recent advancements in comprehending peripheral T-cell lymphomas (PTCLs) validate and
broaden our perspective, highlighting their diverse nature and the varying molecular …

Engineering immune cells to treat hematological malignancies has been a major focus of
research since the first resounding successes of CAR-T-cell therapies in B-ALL. Several …